Histocompatibility Leukocyte Antigen (HLA)-A*2402 Restricted Peptide Vaccine Therapy in Patients With Breast Cancer

NCT00678509 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

14

Enrollment

OTHER

Sponsor class

Stopped Lack of financial support

Conditions

Breast Cancer

Interventions

BIOLOGICAL: TTK peptide mixed with Montanide ISA 51

Sponsor

Tokyo University

Collaborators

[object Object]